NANEXA Stock Overview
Nanexa AB (publ) operates as a nanotechnology drug delivery company.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Nanexa AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.61 |
| 52 Week High | kr3.94 |
| 52 Week Low | kr0.60 |
| Beta | 1.38 |
| 1 Month Change | -18.11% |
| 3 Month Change | -44.40% |
| 1 Year Change | -83.67% |
| 3 Year Change | -93.53% |
| 5 Year Change | -93.27% |
| Change since IPO | -93.81% |
Recent News & Updates
Recent updates
Shareholder Returns
| NANEXA | SE Medical Equipment | SE Market | |
|---|---|---|---|
| 7D | -8.5% | 5.2% | 1.4% |
| 1Y | -83.7% | -8.9% | 8.6% |
Return vs Industry: NANEXA underperformed the Swedish Medical Equipment industry which returned -61.4% over the past year.
Return vs Market: NANEXA underperformed the Swedish Market which returned 4.4% over the past year.
Price Volatility
| NANEXA volatility | |
|---|---|
| NANEXA Average Weekly Movement | 9.1% |
| Medical Equipment Industry Average Movement | 8.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in SE Market | 13.3% |
| 10% least volatile stocks in SE Market | 3.6% |
Stable Share Price: NANEXA's share price has been volatile over the past 3 months.
Volatility Over Time: NANEXA's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 19 | David Westberg | www.nanexa.com |
Nanexa AB (publ) operates as a nanotechnology drug delivery company. It operates PharmaShell, a nanobased drug delivery platform that is an atomic layer deposition. The company also develops NEX-18, which drives the development of a PharmaShell that targets myelodysplastic Syndrome and Acute Myeloid Leukemia; NEX-20 for the treatment of multiple myeloma; and NEX-22 for the treatment of type 2 diabetes.
Nanexa AB (publ) Fundamentals Summary
| NANEXA fundamental statistics | |
|---|---|
| Market cap | kr82.23m |
| Earnings (TTM) | -kr76.40m |
| Revenue (TTM) | kr59.16m |
1.4x
P/S Ratio-1.1x
P/E RatioIs NANEXA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NANEXA income statement (TTM) | |
|---|---|
| Revenue | kr59.16m |
| Cost of Revenue | kr27.71m |
| Gross Profit | kr31.45m |
| Other Expenses | kr107.85m |
| Earnings | -kr76.40m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 03, 2024
| Earnings per share (EPS) | -0.56 |
| Gross Margin | 53.16% |
| Net Profit Margin | -129.14% |
| Debt/Equity Ratio | 4.2% |
How did NANEXA perform over the long term?
See historical performance and comparison